The earnings call highlighted strong performance in the Canada medical business and significant restructuring efforts aimed at cost reduction and operational improvements. However, these were offset by notable underperformance in international markets, challenges with Acreage Holdings, and gross margin pressures. While there are positive signs from new product innovations and restructuring efforts, the financial challenges and market underperformance present significant hurdles.

Company Guidance -

Q2 2026

During Canopy Growth's fourth quarter and fiscal year 2025 financial results conference call, several key metrics and strategic guidance were highlighted. The company reported a 13% growth in its Canadian medical business for fiscal 2025, despite a decline in the broader market. Canopy streamlined its operations by reducing a third of its lowest-performing SKUs, focusing on high-demand product categories such as high-potency flower, pre-rolls, and vapes, and targeting an annual operating expense reduction of at least $20 million over the next 12 to 18 months. Additionally, Canopy made a $100 million U.S. early prepayment on its senior secured term loan, reducing annual interest expenses by approximately $13 million U.S. Efforts to improve supply chain synchronization resulted in increased fill rates from the mid-80s to mid-90s percentage range. Looking ahead, Canopy aims to achieve positive adjusted EBITDA and generate positive free cash flow by accelerating growth in its global medical cannabis and Canadian adult-use businesses, and by launching a new device from Storz & Bickel later in the year.

Strong Performance in Canada Medical Business

The Canada medical business grew sales by 13% year-over-year, benefiting from a shift towards insurer patients and a larger product assortment in the Spectrum online store.

Restructuring and Cost Reduction

Canopy Growth has restructured its operations to improve synchronization and reduce costs, identifying at least $20 million in annual operating expense reductions over the next 12 to 18 months.

Improvement in Adjusted EBITDA

There was a year-over-year improvement in adjusted EBITDA, despite missing the target of positive adjusted EBITDA for fiscal 2025.

Positive Early Signs from Product Innovations

New products such as Claybourne infused pre-rolls and Tweed and 7ACRES all-in-one vapes have shown positive early consumer response, with encouraging market share growth.

Canopy Growth (TSE:WEED) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:WEED Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2026 (Q2)	-0.22 / -	-1.48	―	―	―
Aug 08, 2025	2026 (Q1)	-0.23 / -0.22	-1.6	86.25% (+1.38)	―	―
May 30, 2025	2025 (Q4)	-0.46 / -1.43	-1.03	-38.83% (-0.40)	―
Feb 07, 2025	2025 (Q3)	-0.47 / -1.11	-2.62	57.63% (+1.51)	―
Nov 08, 2024	2025 (Q2)	-0.46 / -1.48	-4.3	65.58% (+2.82)	―
Aug 09, 2024	2025 (Q1)	-0.46 / -1.60	-0.7	-128.57% (-0.90)	―
May 30, 2024	2024 (Q4)	-0.44 / -1.03	-12.8	91.95% (+11.77)	―
Feb 09, 2024	2024 (Q3)	-0.50 / -2.62	-5.4	51.48% (+2.78)	―
Nov 09, 2023	2024 (Q2)	-1.57 / -4.30	-4.7	8.51% (+0.40)	―
Aug 09, 2023	2024 (Q1)	-1.77 / -0.70	-52.3	98.66% (+51.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:WEED Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 30, 2025	C$2.36	C$1.80	-23.73%
Feb 07, 2025	C$3.99	C$2.89	-27.57%
Nov 08, 2024	C$6.30	C$5.90	-6.35%
Aug 09, 2024	C$9.49	C$8.70	-8.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.